Statements (91)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:accessibility |
varies widely across the globe
|
| gptkbp:advises |
recommend testing high-risk populations
|
| gptkbp:affects |
can include liver failure
can include liver cancer |
| gptkbp:alcohol_content |
should be avoided
|
| gptkbp:associated_with |
liver disease
|
| gptkbp:catch_rate |
declining in some developed countries
|
| gptkbp:caused_by |
gptkb:hepatitis_C
|
| gptkbp:clinical_trial |
ongoing for new treatments
|
| gptkbp:collaborations |
aim to eliminate hepatitis C by 2030
between countries and organizations |
| gptkbp:cultural_practices |
associated with drug use
|
| gptkbp:data_usage |
higher in healthcare settings without precautions
|
| gptkbp:diet |
healthy diet to support liver health
|
| gptkbp:discovered_by |
gptkb:1989
gptkb:Michael_Houghton |
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:film_score |
used to evaluate liver health
|
| gptkbp:genetic_diversity |
six genotypes
high among different strains associated with a better response to treatment common in Southeast Asia found mainly in South Africa linked to liver disease more common in the Middle East most common genotype in the US |
| gptkbp:healthcare |
gptkb:Centers_for_Disease_Control_and_Prevention
due to high transmission rates major public health concern |
| https://www.w3.org/2000/01/rdf-schema#label |
hepatitis C virus
|
| gptkbp:influenced_by |
recommended for management
|
| gptkbp:is_adopted_by |
may be necessary in severe cases
|
| gptkbp:is_involved_in |
help patients cope with diagnosis
|
| gptkbp:is_popular_in |
approximately 71 million people infected
|
| gptkbp:is_protected_by |
avoid sharing needles
screening blood donations |
| gptkbp:is_recognized_by |
in patients with non-A, non-B hepatitis
|
| gptkbp:is_tested_for |
Fibro Scan used for non-invasive assessment
|
| gptkbp:is_vulnerable_to |
no effective vaccine available
|
| gptkbp:metabolism |
used to assess liver damage
|
| gptkbp:propagation_method |
blood-to-blood contact
|
| gptkbp:provides_information_on |
updated regularly by health organizations
|
| gptkbp:public_awareness |
important for prevention efforts
aim to reduce stigma and promote testing aim to reduce stigma |
| gptkbp:receives_funding_from |
increased in recent years
|
| gptkbp:research |
ongoing for vaccine development
|
| gptkbp:risk_factor |
intravenous drug use
blood transfusions before 1992 healthcare exposure healthcare exposure in some countries increases with chronic infection duration sharing personal items like razors |
| gptkbp:scholarships |
available through various organizations
can be affected by chronic illness |
| gptkbp:scientific_classification |
gptkb:World_Health_Organization
|
| gptkbp:screenings |
for baby boomers in the US
adults born between 1945 and 1965 |
| gptkbp:side_effect |
can be significant for chronic patients
|
| gptkbp:social_responsibility |
gptkb:healthcare_organization
gptkb:HIV varies by region blood test affects millions worldwide often asymptomatic HCVRNA test can lead to liver cancer can lead to liver cirrhosis HIV common in some populations anti-HCV antibody test can lead to cirrhosis can lead to extrahepatic manifestations may resolve spontaneously often requires confirmatory testing with hepatitis B possible |
| gptkbp:symptoms |
fatigue
nausea abdominal pain jaundice loss of appetite |
| gptkbp:training |
beneficial for overall health
|
| gptkbp:transmission |
blood-to-blood contact
|
| gptkbp:treatment |
gptkb:drug
antiviral medications over 95% with direct-acting antivirals can be high in some regions can lead to sustained virologic response required to prevent recurrence |
| gptkbp:bfsParent |
gptkb:Michael_Houghton
|
| gptkbp:bfsLayer |
3
|